Search - tctmd.com

Displaying 781 - 800 of 881

Sort: Relevancy | Date

News Industry News

Boston Scientific Completes Patient Enrollment in PREVAIL Study for First-in-Class WATCHMAN Device

July 02, 2012

News Daily News

RE-LY: Dabigatran Shortens Drug Interruption with No Increased Bleeding

Jason Kahn

June 22, 2012

News Daily News

Door Still Not Shut on CLOSURE I

Yael L. Maxwell

June 15, 2012

News Daily News

Rivaroxaban May be Cost-Effective for A-fib Patients

L.A. McKeown

June 06, 2012

Presentation

Cost-effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation

Presenter: S. Lee

June 05, 2012

Presentation TVT 2012

The Evolving Standard of Care: Oral Antithrombotic Agents for Stroke Prevention in Atrial Fibrillation

Presenter: Gregg Stone

June 05, 2012

Presentation TVT 2012

The Evolving Standard of Care: Atrial Fibrillation Ablation

Presenter: Shephal Doshi

June 05, 2012

News Industry News

CardioFocus Announces Largest Worldwide Study of HeartLight® EAS Acute Clinical Outcomes Presented at Heart Rhythm 2012

June 04, 2012

News Daily News

Watchman Works Just as Well Without Warfarin-Protected Transition

June 01, 2012

Presentation

Watchman LAA Closure in A-fib Patients with Contraindication to Oral Anticoagulation

Presenter: Vivek Y. Reddy

May 30, 2012

News Industry News

FDA Advisory Committee Recommends Against Approval of Oral Anticoagulant XARELTO® to Reduce the Risk of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome

May 23, 2012

News Industry News

Key Clinical Data for St. Jude Medical’s Structural Heart Technologies Revealed at EuroPCR

May 16, 2012

News Industry News

Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy

May 11, 2012

News Daily News

New Oral Anticoagulants Top Warfarin in A-fib Stroke Prevention

May 04, 2012

Presentation

Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) vs. Warfarin in Patients with A-fib

Presenter: Corey S. Miller

May 03, 2012

News Daily News

Risk of Intracranial Hemorrhage, Mortality Lower with Dabigatran in A-fib Patients

L.A. McKeown

April 30, 2012

News Daily News

El Riesgo de Hemorragia Intracraneal y Mortalidad es Más Bajo con Dabigatran en Pacientes que Padecen Fibrilación Auricular

L.A. McKeown

April 30, 2012

Presentation

Intracranial Hemorrhage in A-fib Patients During Anticoagulation with Warfarin or Dabigatran

Presenter: Robert G. Hart

April 27, 2012

News Daily News

ROCKET AF: Stopping Rivaroxaban or Warfarin Equally Harmful in A-fib Patients

Caitlin E. Cox

April 26, 2012

Presentation

Outcomes of Discontinuing Rivaroxaban vs. Warfarin in Patients with Nonvalvular Atrial Fibrillation (A-fib)

Presenter: M. Patel

April 25, 2012

Advertisement

Boston Scientific Completes Patient Enrollment in PREVAIL Study for First-in-Class WATCHMAN Device

RE-LY: Dabigatran Shortens Drug Interruption with No Increased Bleeding

Door Still Not Shut on CLOSURE I

Rivaroxaban May be Cost-Effective for A-fib Patients

Cost-effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation

The Evolving Standard of Care: Oral Antithrombotic Agents for Stroke Prevention in Atrial Fibrillation

The Evolving Standard of Care: Atrial Fibrillation Ablation

CardioFocus Announces Largest Worldwide Study of HeartLight® EAS Acute Clinical Outcomes Presented at Heart Rhythm 2012

Watchman Works Just as Well Without Warfarin-Protected Transition

Watchman LAA Closure in A-fib Patients with Contraindication to Oral Anticoagulation

FDA Advisory Committee Recommends Against Approval of Oral Anticoagulant XARELTO® to Reduce the Risk of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome

Key Clinical Data for St. Jude Medical’s Structural Heart Technologies Revealed at EuroPCR

Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy

New Oral Anticoagulants Top Warfarin in A-fib Stroke Prevention

Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) vs. Warfarin in Patients with A-fib

Risk of Intracranial Hemorrhage, Mortality Lower with Dabigatran in A-fib Patients

El Riesgo de Hemorragia Intracraneal y Mortalidad es Más Bajo con Dabigatran en Pacientes que Padecen Fibrilación Auricular

Intracranial Hemorrhage in A-fib Patients During Anticoagulation with Warfarin or Dabigatran

ROCKET AF: Stopping Rivaroxaban or Warfarin Equally Harmful in A-fib Patients

Outcomes of Discontinuing Rivaroxaban vs. Warfarin in Patients with Nonvalvular Atrial Fibrillation (A-fib)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content